RT Journal Article
SR Electronic
T1 TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 295253
DO 10.1101/295253
A1 Teder, Hindrek
A1 Koel, Mariann
A1 Paluoja, Priit
A1 Jatsenko, Tatjana
A1 Rekker, Kadri
A1 Laisk-Podar, Triin
A1 Kukuškina, Viktorija
A1 Velthut-Meikas, Agne
A1 Žilina, Olga
A1 Peters, Maire
A1 Kere, Juha
A1 Salumets, Andres
A1 Palta, Priit
A1 Krjutškov, Kaarel
YR 2018
UL http://biorxiv.org/content/early/2018/04/05/295253.abstract
AB Targeted next-generation sequencing based biomarker detection methods have become essential for biomedical diagnostics. In addition to their sensitivity and high-throughput capacity, absolute molecule counting based on unique molecular identifier (UMI) has high potential to increase biomarker detection accuracy even further through the reduction of systematic technical biases. Here, we present TAC-seq, a simple and cost-effective targeted allele counting by sequencing method that uses UMIs to estimate the original molecule counts of different biomarker types like mRNAs, microRNAs and cell-free DNA. We applied TAC-seq in three different applications and compared the results with standard sequencing technologies. RNA samples extracted from human endometrial biopsies were analyzed using previously described 57 mRNA-based receptivity biomarkers and 49 selected microRNAs at different expression levels. Cell-free DNA aneuploidy testing was based on cell line (47,XX,+21) genomic DNA. TAC-seq mRNA biomarker profiling showed identical clustering results to full transcriptome RNA sequencing, and microRNA detection demonstrated significant reduction in amplification bias, allowing to determine minor expression changes between different samples that remained undetermined by standard sequencing. The mimicking experiment for cell-free DNA fetal aneuploidy analysis showed that TAC-seq can be applied to count highly fragmented DNA, detecting significant (p=4.8×10−11) excess of molecules in case of trisomy 21. Based on three proof-of-principle applications we show that TAC-seq is a highly accurate and universal method for targeted nucleic acid biomarker profiling.